www.fiercebiotech.com Open in urlscan Pro
104.18.1.165  Public Scan

Form analysis
2 forms found in the DOM

GET /search-results

<form action="/search-results" method="get">
  <div class="container">
    <div class="row mb-4">
      <div class="col-11">
        <div class="text-left element-title xlarge">What are you searching for?</div>
      </div>
      <div class="col-1 search-dismiss align-items-center d-flex justify-content-end"><button type="button" data-dismiss="modal" class="search-modal-toggle"><img src="/themes/custom/quartz_barrio/images/icons/times-regular.svg"
            alt="Dismiss search modal" style="min-width: 30px;"></button></div>
    </div>
    <div class="row search-form mb-4">
      <div class="col d-flex align-items-center"><button class="position-absolute search-modal-submit" type="submit"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="search" class="svg-inline--fa fa-search fa-w-16" role="img"
            xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512">
            <path fill="currentColor"
              d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
            </path>
          </svg></button><input type="text" placeholder="Search" name="fulltext_search" class="w-100 search-modal-input"></div>
    </div>
    <div class="row search-help-text font-weight-light text-align-left">
      <div class="col-md-10"> Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms. <br> Example: +water -Europe </div>
    </div>
  </div>
</form>

GET /search-results

<form action="/search-results" class="search-form row d-flex align-items-center position-relative" method="get">
  <div class="col-auto px-2 d-flex justify-content-center align-items-center position-absolute" style="z-index: 1;"><button type="submit"><svg aria-hidden="true" focusable="false" data-prefix="far" data-icon="search"
        class="svg-inline--fa fa-search fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512">
        <path fill="currentColor"
          d="M508.5 468.9L387.1 347.5c-2.3-2.3-5.3-3.5-8.5-3.5h-13.2c31.5-36.5 50.6-84 50.6-136C416 93.1 322.9 0 208 0S0 93.1 0 208s93.1 208 208 208c52 0 99.5-19.1 136-50.6v13.2c0 3.2 1.3 6.2 3.5 8.5l121.4 121.4c4.7 4.7 12.3 4.7 17 0l22.6-22.6c4.7-4.7 4.7-12.3 0-17zM208 368c-88.4 0-160-71.6-160-160S119.6 48 208 48s160 71.6 160 160-71.6 160-160 160z">
        </path>
      </svg></button></div>
  <div class="col p-0"><input type="text" placeholder="Search" name="fulltext_search" class="w-100 gray-bg font-weight-medium"></div>
</form>

Text Content

Advertisement



Fierce Biotech Continues Here ▼








 * Fierce Pharma
 * Fierce Biotech
 * Fierce Healthcare
 * Fierce Life Sciences Events


 * Research
 * Biotech
   * Clinical Data
   * Venture Capital
   * Deals
 * Medtech
   * Devices
   * Diagnostics
   * AI and Machine Learning
 * CRO
 * Special Reports
 * Trending Topics
   * Cell & Gene Therapy
   * COVID-19
   * Emerging Biopharma
   * Decentralized Trials
 * Podcasts

 * Resources
   * Events
   * Webinars
 * Subscribe

What are you searching for?


Enclose phrases in quotes. Use a + to require a term in results and - to exclude
terms.
Example: +water -Europe
Subscribe

 * Research
 * Biotech
   * Clinical Data
   * Venture Capital
   * Deals
   
 * Medtech
   * Devices
   * Diagnostics
   * AI and Machine Learning
   
 * CRO
 * Special Reports
 * Trending Topics
   * Cell & Gene Therapy
   * COVID-19
   * Emerging Biopharma
   * Decentralized Trials
   
 * Podcasts

 * Resources
   * Events
   * Webinars
   
 * Subscribe

 * Fierce Pharma
 * Fierce Biotech
 * Fierce Healthcare
 * Fierce Life Sciences Events



CRO


CUREBASE ATTRACTS GILEAD AS BACKER IN $40M FINANCING TO EXPAND BUSINESS

By Gareth MacdonaldMay 5, 2022 10:30am
CurebaseGilead Sciencescontract research organizationclinical trial
Curebase plans to expand the range of clinical trial services it offers to drug
industry customers thanks to $40 million in new funding. (noman
jawaid/iStock/Getty Images Plus)

Curebase says $40 million raised through an investment round that attracted
Gilead Sciences as a backer will fund platform expansion and help the CRO enter
the complex interventional studies market.



San Francisco-based Curebase shared details of the series B funding round this
week explaining that, in addition to existing investors GGV Capital, Bold
Capital and Xfund, U.S. drugmaker Gilead made a strategic investment.

Curebase and Gilead have worked together "for quite some time now," Curebase CEO
Tom Lemberg told Fierce Biotech. The companies have partnered on expanding
Curebase's software and virtual site capabilities beyond telemedicine-
and ePRO-based studies to more complex, global drug studies, he added. 



whitepaper


UTILIZING AUGMENTED INTELLIGENCE TO DRIVE OPTIMAL DECISIONS THROUGHOUT THE
SPECIALTY AND RARE DISEASE PRODUCT LIFECYCLE

Sponsored by IPM.ai

For the development and commercialization of life improving therapies for rare
diseases, the typical approach falls short. Enter augmented intelligence, a
concept that utilizes ML/AI and RWD to enhance, rather than replace human
decision-making.

LEARN MORE

“The strategic investment by Gilead signifies further expansion and deepening of
this relationship as the two companies work towards their common goal of making
their studies more accessible to patients no matter what the trial," Lemberg
said. 


RELATED

Curebase adds real-world data, AI experts to board in decentralized trial push

As part of this, Curebase plans to expand the range of clinical trial services
it offers to drug industry customers. Lemberg said his company focuses
on gastrointestinal health, infectious disease, mental health, central nervous
system disorders, oncology and women’s health. The goal is "to go beyond that"
thanks to the new funding.

"Curebase will tackle complex interventional studies in a modern,
patient-centric way," he said. 



The new funding will also further the development of Curebase’s business with an
eye on patient centricity. Lemberg said the firm will invest in mobile
applications, expansion of its EDC systems, data management and remote
monitoring technology.

BiotechCROseries B



RESOURCE CENTER

REPORT


ASCO 2021 HIGHLIGHTS

The ASCO Annual Meeting gathers oncology professionals from around the world to
discuss the latest in cancer research and treatment. This year's event included
more than 2,500 abstract presentations - and while each study is valuable, we
want to share comments on a few topics of particular interest. Read more.

ARTICLE


MANAGING CLINICAL TRIAL COMPLEXITY

The three factors driving up average study duration, and how to
respond. Complexity isn't going anywhere, so instead of reducing these factors,
let's make better ways to manage them  Learn more.

ARTICLE


RBQM IS OUR FUTURE

Let's talk about the future of clinical trials. There's no crystal ball, but we
have plenty of data - and it shows the growing need for risk-based quality
management (RBQM) in clinical research. Read more.

Our Newsletter






RELATED ARTICLES

BD tightens up revenue guidance after completing Embecta diabetes spinoff
May 5, 2022 11:24am
BioCryst's voluntary pause turns FDA-hold as investigation reveals likely
culprit behind safety signals
May 5, 2022 11:11am
Intellia puts pedal to the metal as 3 new candidates prepped for clinic
May 5, 2022 11:00am
BerGenBio shifts focus from COVID—to COVID in new business strategy update
May 5, 2022 10:57am
See more articles
 * Connect
   * The Team
   * Advertise
 * Join Us
   * Newsletters
   * Resources
   * RSS Feeds
 * Our Brands
   * Fierce Pharma
   * Fierce Biotech
   * Fierce Healthcare
 * Our Events
   * Life Sciences Events

 * ©2022 Questex LLC All rights reserved.
 * Terms of use
 * Privacy Policy


ABCDEFGHIJKLMNOPQRSTUVWXYZabcdefghijklmnopqrstuvwxyz0123456789-_~x